MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Moderna, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$125.62|
|52 Week High||US$376.65|
|52 Week Low||US$115.03|
|1 Month Change||-9.35%|
|3 Month Change||-27.14%|
|1 Year Change||-58.46%|
|3 Year Change||784.65%|
|5 Year Change||n/a|
|Change since IPO||575.38%|
Recent News & Updates
Moderna gets EMA review for Omicron BA.4/BA.5 targeting booster shot for aged 12, above
The European Medicines Agency (EMA) accepted Moderna's (NASDAQ:MRNA) application for conditional marketing authorization of a 50 µg booster dose of the Omicron-containing bivalent COVID booster vaccine mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) in adults 12 years and older. Spikevax bivalent Original/Omicron BA.4-5 is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine targeting the Omicron variant BA.4/BA.5, Moderna said in a Sept. 28 press release. "Following the recent approval of our BA.1 targeting vaccine in Europe, our BA.4/BA5 Omicron targeting vaccine will now bring a second option to help protect people across Europe as we head into the winter months," said Moderna CEO Stéphane Bancel. MRNA +0.14% to $122.40 premarket Sept. 28
EMA aims to start review of Moderna's Omicron BA.4/5 adapted shot by end of September
The European drug regulator expects to start a review of Moderna's (NASDAQ:MRNA) Omicron-subvariant adapted vaccine by the end of this month. "Discussions are ongoing with Moderna in preparation for an application for a Spikevax BA.4/5 adapted bivalent vaccine," the European Medicines Agency's (EMA) Head of Biological Health Threats and Vaccines Strategy Marco Cavaleri said in a press briefing on Tuesday. The EMA has for now recommended approving Pfizer (PFE) and German partner BioNTech's (BNTX) BA.4/5 adapted COVID-19 vaccine, which it did last week. Moderna (MRNA) has so far received conditional marketing approvals in the European Union for its Spikevax COVID-19 vaccine targeting the original SARS-CoV-2 strain and a bivalent shot targeting the original strain and the Omicron BA.1 variant. The EMA has also recommended converting the conditional approvals for MRNA into standard marketing authorizations. Moderna (MRNA) stock +4.2% to $133.21 in morning trading.
Moderna CEO open to providing COVID shots to China; mulls building mRNA facility in Japan - Reuters
Moderna (NASDAQ:MRNA) CEO Stephane Bancel said that the company has discussed with the Chinese government about providing COVID-19 vaccines, but no decision has been reached, Reuters reported. Bancel declined to comment that if Moderna had filed for approval of the vaccine in China but noted that company was open to supplying and had the capacity, the report added. Bancel, who was speaking in Tokyo said that the company is also thinking of setting up facilities in Japan to manufacture mRNA-based products, the report added. On Sept. 12, Japan's Ministry of Health, Labour and Welfare approved Moderna's Omicron-targeting bivalent COVID-19 booster vaccine. Spikevax Bivalent Original/Omicron contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant BA.1.
|MRNA||US Biotechs||US Market|
Return vs Industry: MRNA underperformed the US Biotechs industry which returned -20.8% over the past year.
Return vs Market: MRNA underperformed the US Market which returned -18.2% over the past year.
|MRNA Average Weekly Movement||8.8%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: MRNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MRNA's weekly volatility (9%) has been stable over the past year.
About the Company
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
|MRNA fundamental statistics|
Is MRNA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRNA income statement (TTM)|
|Cost of Revenue||US$6.51b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||35.93|
|Net Profit Margin||61.12%|
How did MRNA perform over the long term?See historical performance and comparison